JP2019116465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019116465A5 JP2019116465A5 JP2018211118A JP2018211118A JP2019116465A5 JP 2019116465 A5 JP2019116465 A5 JP 2019116465A5 JP 2018211118 A JP2018211118 A JP 2018211118A JP 2018211118 A JP2018211118 A JP 2018211118A JP 2019116465 A5 JP2019116465 A5 JP 2019116465A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methoxy
- pharmaceutical composition
- dihydro
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229960004316 cisplatin Drugs 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 6
- -1 4-Methoxy-6-methyl-2-oxo-1,2-dihydro-pyridine-3-yl Chemical group 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960004562 Carboplatin Drugs 0.000 claims 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- RXCVUHMIWHRLDF-UHFFFAOYSA-N ClC1=C2CCN(C(C2=C(C(=C1)C(C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)C(C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-UHFFFAOYSA-N 0.000 claims 1
- RXCVUHMIWHRLDF-HXUWFJFHSA-N ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O Chemical compound ClC1=C2CCN(C(C2=C(C(=C1)[C@@H](C1COC1)OC)Cl)=O)CC=1C(NC(=CC=1OC)C)=O RXCVUHMIWHRLDF-HXUWFJFHSA-N 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
Claims (10)
- 5,8−ジクロロ−2−[(4−メトキシ−6−メチル−2−オキソ−1,2−ジヒドロ−ピリジン−3−イル)メチル]−7−[メトキシ(オキセタン−3−イル)メチル]−3,4−ジヒドロイソキノリン−1(2H)−オンまたは薬学的に許容できるその塩を含む医薬組成物であって、対象におけるがん処置に白金系抗新生物剤または薬学的に許容できるその塩と組合せて用いるための医薬組成物。
- がんが小細胞肺がんである、請求項1に記載の医薬組成物。
- 小細胞肺がんが、進展期疾患として分類される、請求項2に記載の医薬組成物。
- 5,8−ジクロロ−2−[(4−メトキシ−6−メチル−2−オキソ−1,2−ジヒドロ−ピリジン−3−イル)メチル]−7−[メトキシ(オキセタン−3−イル)メチル]−3,4−ジヒドロイソキノリン−1(2H)−オンが、5,8−ジクロロ−2−[(4−メトキシ−6−メチル−2−オキソ−1,2−ジヒドロ−ピリジン−3−イル)メチル]−7−[(R)−メトキシ(オキセタン−3−イル)メチル]−3,4−ジヒドロイソキノリン−1(2H)−オンである、請求項1から3のいずれか一項に記載の医薬組成物。
- 白金系抗新生物剤が、シスプラチンおよびカルボプラチンからなる群から選択される、請求項1から4のいずれか一項に記載の医薬組成物。
- 白金系抗新生物剤がシスプラチンである、請求項1から5のいずれか一項に記載の医薬組成物。
- さらにエトポシドと組み合わせて用いるための、請求項1から6のいずれか一項に記載の医薬組成物。
- 5,8−ジクロロ−2−[(4−メトキシ−6−メチル−2−オキソ−1,2−ジヒドロ−ピリジン−3−イル)メチル]−7−[(R)−メトキシ(オキセタン−3−イル)メチル]−3,4−ジヒドロイソキノリン−1(2H)−オンまたは薬学的に許容できるその塩とシスプラチンとを含み、前記5,8−ジクロロ−2−[(4−メトキシ−6−メチル−2−オキソ−1,2−ジヒドロ−ピリジン−3−イル)メチル]−7−[(R)−メトキシ(オキセタン−3−イル)メチル]−3,4−ジヒドロイソキノリン−1(2H)−オンまたは薬学的に許容できるその塩と、前記シスプラチンとが、それぞれ別個の投薬単位剤形であるキット。
- 前記5,8−ジクロロ−2−[(4−メトキシ−6−メチル−2−オキソ−1,2−ジヒドロ−ピリジン−3−イル)メチル]−7−[(R)−メトキシ(オキセタン−3−イル)メチル]−3,4−ジヒドロイソキノリン−1(2H)−オンまたは薬学的に許容できるその塩と、前記シスプラチンとが、順次投与される、請求項8に記載のキット。
- 5,8−ジクロロ−2−[(4−メトキシ−6−メチル−2−オキソ−1,2−ジヒドロ−ピリジン−3−イル)メチル]−7−[(R)−メトキシ(オキセタン−3−イル)メチル]−3,4−ジヒドロイソキノリン−1(2H)−オンまたは薬学的に許容できるその塩と、シスプラチンとを含む医薬組成物。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762585781P | 2017-11-14 | 2017-11-14 | |
US62/585781 | 2017-11-14 | ||
US201862628314P | 2018-02-09 | 2018-02-09 | |
US62/628314 | 2018-02-09 | ||
US201862684832P | 2018-06-14 | 2018-06-14 | |
US62/684832 | 2018-06-14 | ||
US201862739990P | 2018-10-02 | 2018-10-02 | |
US62/739990 | 2018-10-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019116465A JP2019116465A (ja) | 2019-07-18 |
JP2019116465A5 true JP2019116465A5 (ja) | 2021-11-18 |
JP7201400B2 JP7201400B2 (ja) | 2023-01-10 |
Family
ID=64453535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018211118A Active JP7201400B2 (ja) | 2017-11-14 | 2018-11-09 | Ezh2阻害剤組合せ療法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US11529344B2 (ja) |
EP (1) | EP3710057A1 (ja) |
JP (1) | JP7201400B2 (ja) |
KR (1) | KR20200088386A (ja) |
CN (1) | CN111356478A (ja) |
AU (1) | AU2018369841A1 (ja) |
BR (1) | BR112020008325A2 (ja) |
CA (1) | CA3082287C (ja) |
IL (1) | IL274415A (ja) |
MX (1) | MX2020004731A (ja) |
RU (1) | RU2754131C1 (ja) |
SG (1) | SG11202003477QA (ja) |
TW (1) | TWI698238B (ja) |
WO (1) | WO2019097369A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021063331A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
EP2328919A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
SI2566327T1 (sl) | 2010-05-07 | 2017-07-31 | Glaxosmithkline Llc | Indoli |
WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
KR102373074B1 (ko) | 2010-09-10 | 2022-03-11 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
KR101339500B1 (ko) | 2011-10-18 | 2013-12-09 | 경상대학교산학협력단 | 쌀벌레 방제용 소형 패치 및 젤 |
JP6138813B2 (ja) | 2011-11-28 | 2017-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗pd−l1抗体及びその使用 |
US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
EP2900653A1 (en) | 2012-09-28 | 2015-08-05 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
NZ746054A (en) | 2012-10-15 | 2020-07-31 | Epizyme Inc | Methods of treating cancer |
US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
SG11201506077XA (en) | 2013-02-11 | 2015-08-28 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗pd−1抗体並びにその治療及び診断のための使用 |
US10089842B2 (en) | 2013-10-07 | 2018-10-02 | Google Llc | Smart-home security system with keypad device resistant to anomalous treatment |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CR20200484A (es) * | 2014-06-17 | 2021-04-26 | Pfizer | COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574) |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
EP3303394B1 (en) | 2015-05-29 | 2020-04-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
EA201890630A1 (ru) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | Антитела против pd-1 и способы их применения |
JP2019503391A (ja) * | 2016-01-29 | 2019-02-07 | エピザイム,インコーポレイティド | 癌を処置するための併用療法 |
US10987353B2 (en) * | 2016-05-04 | 2021-04-27 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs |
CN110023338A (zh) | 2016-12-08 | 2019-07-16 | 伊莱利利公司 | 用于与抗pd-l1抗体组合的抗tim-3抗体 |
-
2018
- 2018-11-09 RU RU2020115715A patent/RU2754131C1/ru active
- 2018-11-09 KR KR1020207016752A patent/KR20200088386A/ko not_active Application Discontinuation
- 2018-11-09 CA CA3082287A patent/CA3082287C/en active Active
- 2018-11-09 BR BR112020008325-9A patent/BR112020008325A2/pt not_active Application Discontinuation
- 2018-11-09 AU AU2018369841A patent/AU2018369841A1/en not_active Abandoned
- 2018-11-09 SG SG11202003477QA patent/SG11202003477QA/en unknown
- 2018-11-09 EP EP18807711.9A patent/EP3710057A1/en active Pending
- 2018-11-09 TW TW107139825A patent/TWI698238B/zh not_active IP Right Cessation
- 2018-11-09 MX MX2020004731A patent/MX2020004731A/es unknown
- 2018-11-09 CN CN201880073705.2A patent/CN111356478A/zh active Pending
- 2018-11-09 US US16/762,388 patent/US11529344B2/en active Active
- 2018-11-09 JP JP2018211118A patent/JP7201400B2/ja active Active
- 2018-11-09 WO PCT/IB2018/058795 patent/WO2019097369A1/en unknown
-
2020
- 2020-05-04 IL IL274415A patent/IL274415A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kocak et al. | Targeting autophagy in disease: established and new strategies | |
JP2017504611A5 (ja) | ||
JP2019524690A5 (ja) | ||
Chae et al. | Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit? | |
JP2012255026A5 (ja) | ||
ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
JP2016518337A5 (ja) | ||
CN108348520A (zh) | Mdm2抑制剂和其组合 | |
JP2015508103A5 (ja) | ||
TWI798199B (zh) | 癌症治療 | |
JP2016508134A5 (ja) | ||
JP2016528162A5 (ja) | ||
JP2006523216A5 (ja) | ||
JP2017519019A5 (ja) | ||
JP2008535785A5 (ja) | ||
JP2018521121A5 (ja) | ||
Kutkowska et al. | Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non‐small cell lung cancer cells | |
Rani et al. | Acetamides: chemotherapeutic agents for inflammation-associated cancers | |
JP6724240B2 (ja) | 疾患の処置におけるネクチニブおよびその薬学的に許容可能な塩の新規な使用 | |
Lee et al. | Antitumor activity of acriflavine in lung adenocarcinoma cell line A549 | |
JP2016526021A5 (ja) | ||
JP2010529038A5 (ja) | ||
JP2014148552A5 (ja) | ||
JP2019116465A5 (ja) | ||
Anderson et al. | Pulmonary nocardiosis in a patient with chronic obstructive pulmonary disease—case report and literature review |